相关实验视频
Updated: Feb 14, 2026

08:16
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
7.3K
降脂药物减少的目标病变比非目标病变再血管化更多:一个队列研究
Elina Mantyniemi1, Mitja Laaperi2, Pasi Karjalainen1
1Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.
Annals of medicine
|February 12, 2026
概括
与新位点标病变 (NTL) 相比,在冠状动脉支架后,静止剂药物坚持显著降低了标病变 (TL) 重血管化. 糖尿病和更长的支架长度增加了TL风险,而他类药物提供了保护.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 支架植入后的长期动脉样硬化进展尚未完全理解.
- 确定目标病变 (TL) 与新地点目标病变 (NTL) 冠状动脉狭窄的预测因子至关重要.
研究的目的:
- 确定预测冠状动脉疾病进展的因素,如TL或NTL狭窄.
- 评估药物坚持和患者特征对造后病变发展的影响.
主要方法:
- 1970年接受皮肤冠状动脉支架的患者的前性队列登记.
- 十年的随访,将新的缺血病变归类为TL或NTL.
- 对心血管事件,再血管化率和相关风险因素的分析.
主要成果:
- 总共有639名 (32.4%) 患者在平均9.5年的随访期间经历了心血管事件.
- 目标病变 (TL) 事件比新地点目标病变 (NTL) 事件早发生 (1.2 vs 4.3年).
- 良好的他类药物坚持 (>80%) 降低了TL再血管化几率 (OR 0.45),而糖尿病 (OR 2.07) 和增长的支架长度 (OR 1.26) 提高了TL几率.
结论:
- 与新位点标病变 (NTL) 相比,对他类药物的坚持是预防标病变 (TL) 重血管化的关键因素.
- 糖尿病和更长的支架长度与TL事件的风险增加有关.
- 了解这些预测因素可以优化冠状动脉支架患者的长期管理策略.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Vapor Pressure Lowering
31.5K
The equilibrium vapor pressure of a liquid is the pressure exerted by its gaseous phase when vaporization and condensation are occurring at equal rates:
31.5K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview
10.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Target Cell Response to Hormones
5.8K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Pharmacogenomics: Identification of New Drug Targets
3
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
3

